公开(公告)号：US09212182B2

公开(公告)日：2015-12-15

申请号：US14302337

申请日：2014-06-11

Applicant: AMGEN INC.

Inventor： Matthew Weiss ,  Alessandro Boezio ,  Christiane Boezio ,  John R. Butler ,  Margaret Yuhua Chu-Moyer ,  Erin F. Dimauro ,  Thomas Dineen ,  Russell Graceffa ,  Angel Guzman-Perez ,  Hongbing Huang ,  Charles Kreiman ,  Daniel La ,  Isaac E. Marx ,  Benjamin Charles Milgrim ,  Hanh Nho Nguyen ,  Emily Peterson ,  Karina Romero ,  Brian Sparling

IPC: A61K31/00 ,  C07D215/00 ,  C07D471/04 ,  C07D413/12 ,  C07D401/12 ,  C07D413/14 ,  C07D417/12 ,  C07C53/18 ,  C07D215/227 ,  C07D403/12 ,  C07D215/36 ,  C07D241/44

CPC classification number: C07D417/14 ,  C07C53/18 ,  C07D215/227 ,  C07D215/36 ,  C07D241/44 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04

Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

Abstract translation: 本发明提供式I化合物及其药学上可接受的盐，其是电压门控钠通道的抑制剂，特别是Nav1.7。 该化合物可用于治疗与钠通道活性相关的疾病，例如疼痛障碍和瘙痒。 还提供含有本发明化合物的药物组合物。